DDW Editor Reece Armstrong speaks to Rick Pauls, CEO of DiaMedica, about the company’s efforts in ischemic diseases and the challenges of drug discovery in this field. RA: How did DiaMedica decide to explore the therapy area of ischemia? RP: Ischemic diseases driven by restricted blood flow and endothelial dysfunction, such as preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), have […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!